Pharmacoeconomic review report. Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) (Gilead Sciences Canada, Inc.).
Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX; Vosevi) is a single tablet that combines sofosbuvir with velpatasvir and voxilaprevir. It is recommended as a 12-week, single-tablet regimen for the treatment of chronic hepatitis C virus (HCV) infection for patients without cirrhosis or with compens...
Saved in:
| Online Access: |
http://www.ncbi.nlm.nih.gov/books/NBK534109/ Full text |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health,
2018
|
| Series: | Common drug review clinical review report.
|
| Subjects: |
